CNS Pharmaceuticals, Inc. has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $4,000,000.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, CNS Pharmaceuticals, Inc. is raising $4,000,000.00 in new funding. About CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company’s lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas. Based on human clinical trial data, our lead drug called Berubicin, which was developed at a leading U.S. comprehensive cancer center, has been shown to get across the blood brain barrier and kill brain tumor cells not reachable by other therapies. In other words, Berubicin may become an effective treatment against glioblastoma, the most aggressive type of brain cancer.
To learn more about CNS Pharmaceuticals, Inc., visit http://cnspharma.com/
Contact:
John Climaco, President and Chief Executive Officer
800-946-9185
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.